656 related articles for article (PubMed ID: 21929518)
1. The effects of three phosphodiesterase type 5 inhibitors on ejaculation latency time in lifelong premature ejaculators: a double-blind laboratory setting study.
Gökçe A; Halis F; Demirtas A; Ekmekcioglu O
BJU Int; 2011 Apr; 107(8):1274-7. PubMed ID: 21929518
[TBL] [Abstract][Full Text] [Related]
2. In vitro measurement of ejaculation latency time (ELT) and the effects of vardenafil on ELT on lifelong premature ejaculators: placebo-controlled, double-blind, cross-over laboratory setting.
Gökçe A; Demirtas A; Halis F; Ekmekcioglu O
Int Urol Nephrol; 2010 Dec; 42(4):881-7. PubMed ID: 20174968
[TBL] [Abstract][Full Text] [Related]
3. The effects of phosphodiesterase type 5 inhibitors on penile rigidity variables during a period with no sexual stimulation: a laboratory setting double-blind study.
Gökçe A; Demirtas A; Halis F; Ekmekcioglu O
BJU Int; 2011 Jan; 107(2):264-7. PubMed ID: 20438562
[TBL] [Abstract][Full Text] [Related]
4. Effects of sildenafil citrate on ejaculation latency, detumescence time, and refractory period: placebo-controlled, double-blind, crossover laboratory setting study.
Ekmekçioğlu O; Inci M; Demirci D; Tatlişen A
Urology; 2005 Feb; 65(2):347-52. PubMed ID: 15708051
[TBL] [Abstract][Full Text] [Related]
5. Phosphodiesterase 5 inhibitors in the treatment of premature ejaculation.
Wang WF; Minhas S; Ralph DJ
Int J Androl; 2006 Oct; 29(5):503-09. PubMed ID: 16573707
[TBL] [Abstract][Full Text] [Related]
6. Erectile response to vardenafil in men with a history of nonresponse to sildenafil: a time-from-dosing descriptive analysis.
Hatzichristou DG; Aliotta P; Auerbach S; Barkin J; Lording D; Murdock M; Wilkins HJ; McBride TA; Colopy MW; Carson CC;
Clin Ther; 2005 Sep; 27(9):1452-61. PubMed ID: 16291418
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of sildenafil citrate (Viagra) and tadalafil (Cialis) on sexual responses in Saudi men with erectile dysfunction in routine clinical practice.
Ali ST
Pak J Pharm Sci; 2008 Jul; 21(3):275-81. PubMed ID: 18614424
[TBL] [Abstract][Full Text] [Related]
8. Patterns of switching phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction: results from the Erectile Dysfunction Observational Study.
Hatzichristou D; Haro JM; Martin-Morales A; von Keitz A; Riley A; Bertsch J; Belger M; Wolka AM; Beardsworth A;
Int J Clin Pract; 2007 Nov; 61(11):1850-62. PubMed ID: 17850306
[TBL] [Abstract][Full Text] [Related]
9. Long-term treatment of erectile dysfunction with a phosphodiesterase-5 inhibitor and dose optimization based on nocturnal penile tumescence.
Mathers MJ; Klotz T; Brandt AS; Roth S; Sommer F
BJU Int; 2008 May; 101(9):1129-34. PubMed ID: 18190629
[TBL] [Abstract][Full Text] [Related]
10. Vardenafil improves ejaculation success rates and self-confidence in men with erectile dysfunction due to spinal cord injury.
Giuliano F; Rubio-Aurioles E; Kennelly M; Montorsi F; Kim ED; Finkbeiner AE; Pommerville PJ; Colopy MW; Wachs BH;
Spine (Phila Pa 1976); 2008 Apr; 33(7):709-15. PubMed ID: 18379396
[TBL] [Abstract][Full Text] [Related]
11. Factors that predict changing the type of phosphodiesterase type 5 inhibitor medication among men in the UK.
Kell PD; Hvidsten K; Morant SV; Harnett JP; Bridge S
BJU Int; 2007 Apr; 99(4):860-3. PubMed ID: 17378846
[TBL] [Abstract][Full Text] [Related]
12. SOP conservative (medical and mechanical) treatment of erectile dysfunction.
Porst H; Burnett A; Brock G; Ghanem H; Giuliano F; Glina S; Hellstrom W; Martin-Morales A; Salonia A; Sharlip I;
J Sex Med; 2013 Jan; 10(1):130-71. PubMed ID: 23343170
[TBL] [Abstract][Full Text] [Related]
13. Co-possession of phosphodiesterase type-5 inhibitors (PDE5-I) with nitrates.
Chang LL; Ma M; Allmen Hv; Henderson SC; Harper K; Hornbuckle K
Curr Med Res Opin; 2010 Jun; 26(6):1451-9. PubMed ID: 20394470
[TBL] [Abstract][Full Text] [Related]
14. Effects of vardenafil administration on intravaginal ejaculatory latency time in men with lifelong premature ejaculation.
Aversa A; Pili M; Francomano D; Bruzziches R; Spera E; La Pera G; Spera G
Int J Impot Res; 2009; 21(4):221-7. PubMed ID: 19474796
[TBL] [Abstract][Full Text] [Related]
15. Do vardenafil and tadalafil have advantages over sildenafil in the treatment of erectile dysfunction?
Doggrell S
Int J Impot Res; 2007; 19(3):281-95. PubMed ID: 17183346
[TBL] [Abstract][Full Text] [Related]
16. Tadalafil and vardenafil vs sildenafil: a review of patient-preference studies.
Mirone V; Fusco F; Rossi A; Sicuteri R; Montorsi F
BJU Int; 2009 May; 103(9):1212-7. PubMed ID: 19154480
[TBL] [Abstract][Full Text] [Related]
17. PSD502 improves ejaculatory latency, control and sexual satisfaction when applied topically 5 min before intercourse in men with premature ejaculation: results of a phase III, multicentre, double-blind, placebo-controlled study.
Dinsmore WW; Wyllie MG
BJU Int; 2009 Apr; 103(7):940-9. PubMed ID: 19245438
[TBL] [Abstract][Full Text] [Related]
18. Ten years of phosphodiesterase type 5 inhibitors in spinal cord injured patients.
Lombardi G; Macchiarella A; Cecconi F; Del Popolo G
J Sex Med; 2009 May; 6(5):1248-58. PubMed ID: 19210710
[TBL] [Abstract][Full Text] [Related]
19. Erectile response with vardenafil in sildenafil nonresponders: a multicentre, double-blind, 12-week, flexible-dose, placebo-controlled erectile dysfunction clinical trial.
Carson CC; Hatzichristou DG; Carrier S; Lording D; Lyngdorf P; Aliotta P; Auerbach S; Murdock M; Wilkins HJ; McBride TA; Colopy MW;
BJU Int; 2004 Dec; 94(9):1301-9. PubMed ID: 15610110
[TBL] [Abstract][Full Text] [Related]
20. Prescribing all phosphodiesterase 5 inhibitors to a patient with erectile dysfunction--a realistic and feasible option in everyday clinical practice--outcomes of a simple treatment regime.
Ströberg P; Hedelin H; Ljunggren C
Eur Urol; 2006 May; 49(5):900-7; discussion 907. PubMed ID: 16564126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
